INTERPHEX 2026 Recap: The Foreign Inspection Gap, Live from the Javits Center

On Tuesday, April 21, Global Key Solutions CEO and Founder George Kwiecinski had fifteen minutes on at INTERPHEX 2026 to talk about something he has been working on for over a year: the gap between how much drug product the United States imports and how often the FDA actually inspects the facilities that make it.

Fifteen minutes is not a lot of time. The Quick Fire format forces a speaker to cut the fat. Kwiecinski did exactly that: five chunks and one agenda slide. For anyone who was not in the room, here is what the session covered.

Why This Session Happened Now

Industry can now compute what industry is actually talking about. Sounds obvious, but it is newer than you think.

Kwiecinski opened with a keyword frequency chart that GKS ran across 23 sessions attended at PDA Week 2026 in Denver last month. The top five terms were Regulatory (38 mentions), AI (35), Quality (28), Data (22), and Manufacturing (19). Inspection and Audit came in near the bottom at 5. Data Integrity was dead last at 4.

Not a complaint about PDA. Just an observation about where industry attention is sitting. When Kwiecinski wrote his first paper on FDA warning letter citations in 2024, the analysis was done with regex queries against PDFs on a laptop. Today, the KeyPedia platform indexes 1.5 million FDA and global regulatory data points and can tell you what a room full of quality leaders talked about in an afternoon. The tooling caught up. Without it, a session like this would have been data-free.

The Five Papers Behind the Talk

Kwiecinski wanted the session grounded in peer-reviewed work, not opinion. The reading list:

• Kwiecinski & Yuan - "The Foreign Inspection Gap: FDA GMP Oversight of U.S. Drug Imports, 2014–2024," Journal of Pharmaceutical Innovation (DOI)

• Bao, Buhay & Zheng - "A Dynamic Model for GMP Compliance and Regulatory Science"

• Bao & Zheng - "A Communication Effectiveness Study of the FDA GMP Warning Letters"

• Kwiecinski - "An Analysis of FDA Warning Letter Citations from 2019–2023"

• Higgins, Yan & Chatterjee - "Unpacking the Effects of Adverse Regulatory Events: Evidence from Pharmaceutical Relabeling"

Anyone working in quality or regulatory who has not read the Bao/Zheng communication study should put it on the list. It is one of the few pieces out there that treats Warning Letters as a communication problem instead of a punishment problem.

How an FDA Inspection Actually Works

A lot of people in the industry have never sat through the full inspection lifecycle on paper, so Kwiecinski walked the audience through it. The process spans three entities. FDA/CDER triggers the assignment, whether pre-approval, a referral from complaints or reports, or routine surveillance. ORA/OBIMO executes the inspection and issues the initial classification. The inspected firm sits on the receiving end. Outcomes get classified as NAI (No Action Indicated), VAI (Voluntary Action Indicated), or OAI (Official Action Indicated). A Form FDA 483 is only issued when there are objectionable conditions. A warning letter, import alert, consent decree, or criminal prosecution can follow, or they can be initiated with no prior inspection at all, based on foreign regulatory findings, sample analysis, or adverse event reports.

At one point, Kwiecinski mentioned on stage: this process is not mandatory in a single direction. An investigation can go a lot of different ways depending on what comes up. That is the first thing to internalize if you are on the firm side.

Also worth flagging: FDA issued new draft guidance in 2026 on how firms should respond to 483 observations. Anyone who has not routed that through their quality team yet should do so.

The May 6, 2025 Announcement

On May 6, 2025, FDA announced expanded use of unannounced inspections at foreign manufacturing facilities. The agency said it would build on its existing pilot program in India and China and bring foreign inspection cadence closer to the domestic standard.

Commissioner Makary was direct about why:

"For too long, foreign companies have enjoyed a double standard — given advanced notice before facility inspections, while American manufacturers are held to rigorous standards with no such warning. That ends today. This is a key step for the FDA as part of a broader strategy to get foreign inspections back on track."

Strong statement from a sitting Commissioner. The question Kwiecinski wanted to answer in his session was whether the data behind that statement actually holds up.

The Numbers

Short answer: yes.

Across a panel of 10 countries over 2014 to 2024, foreign drug inspections dropped from 833 in 2019 to 102 in 2021 during the pandemic, recovered to 674 by 2024, and never got back to pre-COVID levels. Over the same period, imports kept climbing. Ireland pharmaceutical imports went from $10.3 billion to about $50 billion. China went from $1.1 billion to $7.8 billion. China's inspection count dropped from a peak of 168 in 2016 to 8 by 2022.

The more useful framing is inspections per billion dollars of imports:

• China: 101.8 inspections per $1B in 2014, falling to 18.3 per $1B in 2024. An 82% decline in inspection intensity.

• Ireland: 92.8% decline in inspection intensity over the decade, while imports grew fivefold.

• India: Held up better than China but still fell from the 40s to the low 20s per $1B.

For the period where the data is cleanest, 2014 to 2019, every additional $1 billion in imports corresponded to roughly 23 fewer inspections. That is the headline number of the paper, and it is not a pandemic artifact. It was happening before COVID.

One more number worth knowing: the foreign deficiency rate (OAI + VAI divided by total drug inspections) sits at 61.9% compared to a U.S. domestic baseline of 49.3%. So when FDA does inspect abroad, the agency finds more problems. Fewer inspections on a population with a higher deficiency rate is the opposite of what a risk-based oversight program should look like.

Why This Matters

A few closing thoughts from the stage:

Deficiency rates have been relatively stable over the decade. Foreign manufacturers are not getting better or worse on average. FDA is just seeing them less. The gap is a resources problem, not a compliance problem.

Advance notice almost certainly understates the real non-compliance rate. If a facility knows an inspector is coming three weeks out, the site will be ready. Unannounced inspections are the only way to get a cleaner read on the true baseline. Which is exactly what the May 2025 announcement is trying to fix.

Mutual Recognition Agreement (MRA) countries, which include Ireland and most of the EU, receive significantly less scrutiny per import dollar than non-MRA countries. That is by design, because FDA relies on partner-country inspectorates for MRA coverage. Whether the current MRA framework is still the right trade-off given how import volumes have shifted is a question worth asking out loud.

What is Happening Right Now

A few things in the policy environment that were not in the paper but came up in Q&A:

• Section 232 tariffs are changing the math on where APIs get sourced.

• New procurement-side scrutiny on generics is pushing buyers to ask harder questions about where their products are actually manufactured.

• NDAA and Country of Origin provisions — the National Defense Authorization Act is starting to bite on federal procurement, and the broader National Drug Supply Chain effort is moving in the same direction.

None of these on their own close the inspection gap. Together they change where pharma chooses to manufacture for the U.S. market, which is the upstream version of the same problem.

The Tools

GKS and KeyPedia were built to make all of this legible to a working Quality or Regulatory team. The research presented at INTERPHEX came out of the same data sitting inside KeyPedia today: Warning Letters, 483s, inspection classifications, recalls, and regulatory actions across multiple health authorities. For a quality lead trying to benchmark CDMOs, watch emerging 483 themes, or pull inspection history on a site before signing a supply agreement, that is the workflow GKS has been building for.

Three next steps for anyone the session landed with: request a demo, browse KeyPedia Lite for free, or read the full paper in the Journal of Pharmaceutical Innovation.

Also on the media page: the PDA Whiteboard Paper on Complete Response Letters that GKS co-authored. Short read, and one of the most-downloaded pieces GKS has put out this year.